Part 1: Performance Analysis

Abbott Laboratories has reported a decline in its total net sales by 14.8% in the first quarter of 2023 as compared to the same period in the previous year. COVID-19-related testing sales had a major impact on its sales, reflecting a decrease in demand for Abbott’s rapid diagnostic tests to detect COVID-19. The net sales were unfavorably impacted by changes in foreign exchange rates as the relatively stronger U.S. dollar decreased total international sales by 5.7 percent and total sales by 3.3 percent. However, excluding the impact of foreign exchange and COVID-19 testing-related sales, Abbott’s total net sales increased by 9.4 percent, indicating impressive underlying growth across other businesses. 

The Pediatric Nutritionals segment saw strong growth in U.S. sales of 36.1 percent for Q1 2023, mainly due to a decrease in Pedialyte® sales, which had increased due to the prevalence of the COVID-19 outbreak in the previous year. Abbott’s Diagnostic Products segment saw a 47.1 percent decrease in sales primarily driven by lower demand for COVID-19 tests. Excluding the impact of foreign exchange, the increases of 3.9 percent in U.S. Adult Nutritionals and 4.4 percent in International Adult Nutritionals and 21.8 percent growth in Other Emerging Markets reflects solid growth in the nutrition business.

Part 2: Forward Looking Analysis

The COVID-19 outbreak had disrupted Abbott’s Diagnostic Products segment in the previous year when Abbott’s rapid diagnostic tests to detect COVID-19 had driven the sales. However, demand for such tests is decreasing, which is adversely affecting the segment sales. The outlook for the segment, therefore, depends on the future demand for COVID-19-related medical devices. Although the COVID-19 pandemic had a negative impact on Abbott’s sales, the impressive underlying growth across its other businesses shows the company's ability to handle the crisis effectively. Abbott’s strategy to acquire select businesses and divest others to focus on core businesses will position the company to rebound more effectively from the pandemic. Abbott also expressed a favorable outlook on the long-term growth of the company at its quarterly earnings call. 

In conclusion, Abbott’s performance for the Q1 2023 reflected a decline in sales, primarily driven by lower demand for COVID-19 tests and foreign exchange impact. However, excluding the impact of foreign exchange and COVID-19 testing-related sales, the underlying sales growth seems promising. The potential for the company to rebound more effectively from the pandemic by focusing on its core businesses and M&A activity could be a promising future for the company as a whole.

XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Abbott Laboratories

Abbott Reports Q1 Decline: Foreign Exchange & COVID Hit Sales. But Excluding That? A 9.4% Increase.

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

Announcement: ABT 8-K Special Filing

Abbott, a global healthcare leader, announced its financial results for the first quarter ended March 31, 2023. The company reported a decrease of 18% in reported sales, but organic sales growth for the underlying base business increased by 10%. This growth was led by Medical Devices, Established Pharmaceuticals, and Nutrition. 

In Nutrition, worldwide sales increased 3.8% reported basis and 10.3% on an organic basis, while Pediatric Nutrition sales globally increased 9.2% reported basis and 18.4% on an organic basis. The Adult Nutrition sector recorded a decrease of 0.5% in reported basis and an increase of 4.6% in organic sales. 

Established Pharmaceuticals sales increased 3.7% in reported basis and 11.1% on an organic basis in the first quarter. Key Emerging Markets include emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. 

In contrast, seasonal respiratory testing resulted in reduced growth in Molecular Diagnostics while world Diagnostics sales increased by 0.2% in reported basis and 4.4% on an organic basis excluding covid-19 testing-related sales. 

Abbott Laboratories reaffirmed its 2023 sales outlook of $43.5 billion excluding the impact of foreign exchange and changes in the regulatory environment.  The company's cash dividend is also noticeable, payable on May 15, 2023, to shareholders of records. 

Overall, Abbott's Q1 results present a strong start to the year, driven by solid organic growth in the Medical Devices, Established Pharmaceuticals, and Nutrition businesses. The company has reaffirmed its 2023 sales outlook, and organic growth continues to be a key focus area for the company. Invested stakeholders can be assured that Abbott is leveraging strategic partnerships for growth and development across its operating segments.

Form 8-K - Current report - Item 2.02 Item 9.01

$ABT reports 10% organic growth in Q1 2023, driven by Medical Devices, Established Pharmaceuticals, and Nutrition businesses.

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Abbott Laboratories: COVID-19 Impact on Financial Performance
Current Analysis:
Abbott Laboratories has had a successful few years, despite the COVID-19 pandemic. Despite the pandemic, Abbott has managed to increase total sales since 2020 due to the introduction of new products across various businesses, as well as higher sales of existing products. Sales in emerging markets increased 5.6 percent in 2022 and 19.6 percent in 2021, excluding the impact of foreign exchange. In the US, Abbott’s sales increased 8.8 percent in 2022 and 3.5 percent in 2021, excluding the impact of foreign exchange. Abbott’s COVID-19 testing-related sales totaled approximately $8.4 billion in 2022, $7.7 billion in 2021, and $3.9 billion in 2020.

Forward-Looking Analysis:
Abbott is continually monitoring the effects of the pandemic on its operations and is taking aggressive steps to limit exposure to COVID-19 and enhance the safety of facilities for its employees. On January 30, 2023, the U.S. government announced that it plans to end the COVID-19 public health emergency on May 11, 2023. Abbott is evaluating the potential impacts of the end of the public health emergency, and it will continue to monitor further regulatory actions from relevant U.S. government agencies and assess potential impacts on pandemic-related government policies and product authorizations. Abbott expects the COVID-19 pandemic to shift to an endemic state in 2023, which would likely result in significantly lower demand for COVID-19 tests. Despite the uncertainly of the pandemic, Abbott has been able to maintain a successful financial performance and is well-positioned for future growth.

Announcement: ABT 10-K Annual Report

Form 8-K - Current report - Item 5.03 Item 9.01

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Abbott Reports Q1 Decline: Foreign Exchange & COVID Hit Sales. But Excluding That? A 9.4% Increase.

Abbott Reports Q1 Decline: Foreign Exchange & COVID Hit Sales. But Excluding That? A 9.4% Increase.

Announcement: ABT 8-K Special Filing

Announcement: ABT 8-K Special Filing

$ABT reports 10% organic growth in Q1 2023, driven by Medical Devices, Established Pharmaceuticals, and Nutrition businesses.

$ABT reports 10% organic growth in Q1 2023, driven by Medical Devices, Established Pharmaceuticals, and Nutrition businesses.

Announcement: ABT 10-K Annual Report

Announcement: ABT 10-K Annual Report

Announcement: ABT 8-K Special Filing

Announcement: ABT 8-K Special Filing

Announcement: ABT SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment

Announcement: ABT SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment